Current Opinion in HIV & AIDS:
Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
Alan L. Landay
Alan L. Landay, PhD is Professor and Chairman of the Department of Immunology/Microbiology at Rush University Medical Center, Chicago Illinois, USA. He received his PhD in immunopathology from the University of Pittsburgh, USA, and did postdoctoral training at the University of Alabama (UAB), USA, in clinical immunology from Dr Max Cooper. He has been at Rush University Medical Center since 1983.
Dr Landay has worked in the field of HIV research for over 30 years. He performed some of the first studies evaluating the immune response of hemophiliac patients while a postdoctoral fellow at UAB. He worked with Abbott Laboratories when moving to Chicago to help in developing the first antibody test for screening the blood supply for HIV. He also helped in developing the first HIV p24 antigen test and published some of the first papers using this assay to diagnose acute HIV disease. Dr Landay has also been a leader in CD4 T cell testing. He chaired the NCCLS committee that wrote the first guideline for standardizing CD4 T Cell measurements by flow cytometry. Subsequently he worked with NIH, CDC, and WHO in implementing global guidelines for CD4 testing. More recently he has worked on point of care HIV diagnostics in helping move these assays forward into resource limited settings. This work was done in collaboration with WHO, Gates Foundation, Clinton Foundation, MSF, Doris Duke Foundation, and Forum for HIV Collaborative Research.
Dr Landay's main research over the past twenty years has focused on studies of the immunopathogenesis of HIV disease. He works to transition basic research findings into clinical therapeutics. He has worked with the AIDS Clinical Trials for 20 years and has served as Chair of the Immune Based Therapeutic Committee and more recently as a member of the End Organ Disease and Inflammation Transformative Science Group. He is principal investigator of the ACTG Immunology Support Laboratory in Chicago. Dr Landay also is pursuing studies of HIV and aging. He is a member of the Office of AIDS Research Panel on HIV and Aging as well as a member of the UNAIDS HIV and Aging group. Through the NIH funded Center for AIDS Research he chairs the HIV and Aging Inter CFAR group that is collaborating with the National Institute of Aging funded Older Americans Independence Centers. Dr Landay holds leadership positions in many national and international organizations. He is Co-Chair of the Office of AIDS Research Etiology and Pathogenesis Panel. He serves as Chair of the NIH funded Women's Interagency HIV Study Science Committee. He chairs the Immune Activation Inflammation Working Group of the ACTG. Dr Landay is principal investigator of the Chicago Developmental Center for AIDS Research. Dr Landay has served on NIH, AmFar, Glazer Pediatrics, and State of California Grant Review Study Sections. He is the former Chair of the NIH/AIDS Vaccine Study Section. He is an author of over 300 peer reviewed papers in the fields of HIV and immunology. He serves as a mentor to graduate students, postdoctoral fellows, and clinical fellows at Rush University. He was recently awarded Professor of the FC Donders Chair at the University of Utrecht, the Netherlands, to pursue studies of immunology and nutrition.
Dr Tae-Wook Chun received his PhD in Biochemistry, Cellular, and Molecular Biology from Johns Hopkins University School of Medicine, USA, in 1997. While working with Dr Robert Siliciano at Johns Hopkins, he identified and characterized latently infected, resting CD4+ T cells in HIV-infected individuals. After receiving his PhD, he pursued postdoctoral work in the Laboratory of Immunoregulation under the direction of Dr Anthony Fauci at the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH). At the NIH, he demonstrated for the first time that the latent HIV reservoir persists in virtually all infected individuals receiving antiretroviral therapy despite effective suppression of plasma viremia. In addition, he demonstrated that early initiation of antiretroviral therapy leads to a decay of the latent viral reservoir and introduced the concept of “virus purging” in HIV-infected individuals. He is currently an Associate Scientist at the NIH and continues to study the role of viral reservoirs in the pathogenesis of HIV disease and is working towards developing therapeutic strategies aimed at achieving a state of functional cure in infected individuals without antiretroviral therapy.